Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.42 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.54 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.52 |
| ▸ | NOS3 | P29474 | 1/20 | 0.50 |
| ▸ | NOS1 | P29475 | 1/20 | 0.50 |
| ▸ | NOS2 | P35228 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | AGXT | P21549 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL3977215 | 1.00 | HRH3 (0.64) | HRH3ALDH1A1TSHRTAAR1PYCR1 | |
| SCHEMBL12374 | 0.97 | HRH3 (0.67) | HRH3ALDH1A1TSHRTAAR1PYCR1 | |
| Phosphine SCHEMBL25337730 | 0.95 | HRH3 (0.64) | HRH3ALDH1A1TSHRTAAR1PYCR1 | |
| Hydrochloric Acid SCHEMBL28688142 | 0.95 | HRH3 (0.64) | HRH3ALDH1A1TSHRTAAR1PYCR1 | |
| SCHEMBL260357 | 0.90 | HRH3 (0.81) | HRH3ALDH1A1TSHRTAAR1PYCR1 | |
| SCHEMBL32689849 | 0.86 | HRH3 (0.54) | HRH3ALDH1A1TSHRTAAR1PYCR1 | |
| SCHEMBL659509 | 0.86 | HRH3 (0.82) | HRH3ALDH1A1TSHRTAAR1NOS3 | |
| SCHEMBL16312619 | 0.81 | PYCR1 (0.65) | HRH3ALDH1A1TSHRTAAR1PYCR1 | |
| Toluene SCHEMBL10462210 | 0.80 | TSHR (0.81) | HRH3ALDH1A1TSHRTAAR1PYCR1 | |
| SCHEMBL12679031 | 0.78 | HRH3 (1.00) | HRH3ALDH1A1TSHRTAAR1PYCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2139461-A2 | AMINO DERIVATIVES TO PREVENT NEPHROTOXICITY AND CANCER | Recepticon Aps (DK) | 2010-01-06 | — | — | EP | disclosed |
| US-20090110720-A1 | Use of compounds for the prevention of drug-induced cell toxicity | RECEPTICON APS (DK) | 2009-04-30 | — | — | US | disclosed |
| US-20090098145-A1 | METHODS AND COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS VIA MODULATION OF MEGALIN ACTIVITY | SIRION THERAPEUTICS, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| EP-2037951-A2 | METHODS AND COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS VIA MODULATION OF MEGALIN ACTIVITY | Sirion Therapeutics, Inc. (US) | 2009-03-25 | — | — | EP | disclosed |
| WO-2008113364-A2 | AMINO DERIVATIVES TO PREVENT NEPHROTOXICITY AND CANCER | RECEPTICON APS (DK) | 2008-09-25 | — | — | WO | disclosed |
| WO-2007150046-A2 | METHODS AND COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS VIA MODULATION OF MEGALIN ACTIVITY | SIRION THERAPEUTICS, INC (US) | 2007-12-27 | — | — | WO | disclosed |
| EP-1809381-A2 | USE OF COMPOUNDS FOR THE PREVENTION OF DRUG-INDUCED CELL TOXICITY | Recepticon ApS (DK) | 2007-07-25 | — | — | EP | disclosed |
| WO-2006037335-A2 | USE OF COMPOUNDS FOR THE PREVENTION OF DRUG-INDUCED CELL TOXICITY | RECEPTICON APS (DK) | 2006-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090110720-A1 | Use of compounds for the prevention of drug-induced cell toxicity | SLC47A1, SLC10A6, SLC47A2 | ACHE 3113/4885SLC6A4 202/4885HRH3 3636/4885 |
| US-20090098145-A1 | METHODS AND COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS VIA MODULATION OF MEGALIN ACTIVITY | ALDH1A2, PDE6C, EYA2 | ACHE 3180/4885SLC6A4 3854/4885HRH3 3316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.